Targeted radiation treatment for advanced prostate cancer without hormone therapy
Official title: Phase II Trial of targeted Radiation with no castration for mcrpc (POTENT-C)
Funded at VA Greater Los Angeles Healthcare System · NIH-11046544 · Data updated 2026-11-12
This study is looking at a new way to treat advanced prostate cancer by using targeted radiation therapy that allows men to keep their testosterone levels normal, with the hope of improving their quality of life while fighting the cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | VA Greater Los Angeles Healthcare System NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | January 1, 2024 |
| Project end | December 31, 2028 |
| Funding year | 2025 |
| NIH project number | 5I01CX002775-02 |
| Project ID | NIH-11046544 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with metastatic castration-resistant prostate cancer who are seeking alternative treatment options.
✕Less likely to help
Patients who have not been diagnosed with mCRPC or those who are not suitable for radiation therapy may not benefit from this research.
What this research studies
This research investigates a new approach for treating metastatic castration-resistant prostate cancer (mCRPC) by using targeted radiation therapy without the need for continuous medical or surgical castration. The study aims to determine if patients can maintain a better quality of life by restoring normal testosterone levels while receiving targeted radiation that specifically attacks cancer cells. By focusing on precision delivery of radiation to metastatic lesions, the research seeks to improve treatment outcomes and overall well-being for patients. Participants will be monitored for both cancer progression and quality of life improvements throughout the trial.
Why it matters
Potential benefit: If successful, this research could significantly enhance the quality of life for patients with mCRPC by reducing side effects associated with hormone therapy.
How similar studies have gone: Previous research has shown promising results with targeted radiation therapies in similar contexts, indicating potential for success in this novel approach.
Where this research is happening
-
VA Greater Los Angeles Healthcare System
Los Angeles, United States Active
Researchers
- Principal investigator: Nickols, Nicholas George — VA Greater Los Angeles Healthcare System
- Study coordinator: Nickols, Nicholas George
Related research
Other NIH-funded projects on the same topics.
-
Dual Targeting of B7-H3 in metastatic prostate cancer
A Johns Hopkins team is testing two targeted therapies against B7-H3 to help people with metastatic castration-resistant prostate cancer feel better and show tumor responses.
-
Hyperactive methylation in a hard-to-treat prostate cancer subtype
Researchers are studying a newly identified methylation-heavy group of advanced prostate cancer to understand its biology and find clues for better treatments.
-
Extending Benefit by Targeting Resistant Lesions in mCRPC
A cancer center plans to identify on-treatment resistant spots in men with metastatic castration-resistant prostate cancer and then use targeted local therapy to those spots while systemic treatment continues.
-
CXCR1/2 inhibitor plus enzalutamide for abiraterone-resistant metastatic prostate cancer
A phase 2 study tests whether adding SX-682 to enzalutamide helps men with advanced prostate cancer that no longer responds to abiraterone.
-
Multidimensional approach to boost PSMA-RPT success in advanced prostate cancer
A cancer research grant aims to better understand why PSMA-targeted radiopharmaceutical therapy works sometimes but not always for advanced prostate cancer, with the goal of making treatments more effective for patients who need them.
-
Targeted radiation approach for prostate cancer without continuous castration
A study testing a targeted radiation plan for men with metastatic castration-resistant prostate cancer to improve outcomes and quality of life by avoiding continuous castration for those receiving PSMA-directed therapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.